Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging

Psychiatry Research - Neuroimaging

Volumn 156, Issue 1, 2007, Pages 75-82

  Yeh, Chin Bin ^a   Lee, Chung Shian ^b   Ma, Kuo Hsing ^c   Lee, Meei Shyuan ^c   Chang, Chia Jung ^c   Huang, Wen Sheng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Lioying Chi Mei Hospital   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

99mTC TRODAT 1; Dopamine transporter; Methylphenidate; Tourette's syndrome

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; METHYLPHENIDATE;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; NEUROIMAGING; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TIC;

ADULT; BRAIN; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; HUMANS; MALE; METHYLPHENIDATE; ORGANOTECHNETIUM COMPOUNDS; PUTAMEN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOURETTE SYNDROME; TROPANES;

EID: 34548478369     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2007.01.003     Document Type: Article

References (47)

1. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., and Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128 (2005) 2760-2762
2. Albin R.L. Neurobiology of basal ganglia and Tourette syndrome: striatal and dopamine function. Advances in Neurology 99 (2006) 99-106
3. Albin R.L., Koeppe R.A., Bohnen N.I., Nichols T.E., Meyer P., Wernette K., Minoshima S., Kilbourn M.R., and Frey K.A. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61 (2003) 310-315
4. Berridge K.C., Aldridge J.W., Houchard K.R., and Zhuang X. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biology 3 (2005) 4
5. Bloch M.H., Leckman J.F., Zhu H., and Peterson B.S. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology 65 (2005) 1253-1258
6. Bloch M.H., Peterson B.S., Scahill L., Otka J., Katsovich L., Zhang H., and Leckman J.F. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Archives of Pediatrics and Adolescent Medicine 160 (2006) 65-69
7. 11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. Journal of Neural Transmission 113 (2005) 187-193
8. Chen R., Han D.D., and Gu H.H. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. Journal of Neurochemistry 94 (2005) 352-359
9. 123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Research: Neuroimaging 130 (2004) 85-95
10. Cohen D.J., Shaywitz B.A., Young J.G., Carbonari C.M., Nathanson J.A., Lieberman D., Bowers Jr. M.B., and Maas J.W. Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette: norepinephrine, serotonin, and dopamine. Journal of the American Academy of Child Psychiatry 18 (1979) 320-341
11. 99mTc]TRODAT-1 to the central dopamine transporters in rats. European Journal of Nuclear Medicine 25 (1998) 31-39
12. Edwards M.J., Dale R.C., Church A.J., Trikouli E., Quinn N.P., Lees A.J., Giovannoni G., and Bhatia K.P. Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies. Movement Disorders 19 (2004) 1190-1196
13. Eidelberg D., Moeller J.R., Antonini A., Kazumata K., Dhawan V., Budman C., and Feigin A. The metabolic anatomy of Tourette's syndrome. Neurology 48 (1997) 927-934
14. Ernst M., Zametkin A.J., Jons P.H., Matochik J.A., Pascualvaca D., and Cohen R.M. High presynaptic dopaminergic activity in children with Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry 38 (1999) 86-94
15. Federici M., Geracitano R., Bernardi G., and Mercuri N.B. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biological Psychiatry 57 (2005) 361-365
16. Fukui R., Svenningsson P., Matsuishi T., Higashi H., Nairn A.C., Greengard P., and Nishi A. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. Journal of Neurochemistry 87 (2003) 1391-1401
17. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., and Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Research Reviews 26 (1998) 148-153
18. Golden, G.S., 1988. The relationship between stimulant medication and tics. Pediatric Annals 17, 405-406, 408.
19. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
20. Heinz A., Knable M.B., Wolf S.S., Jones D.W., Gorey J.G., Hyde T.M., and Weinberger D.R. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 51 (1998) 1069-1074
21. 99mTc]TRODAT-1 imaging. Journal of Nuclear Medicine 42 (2001) 1303-1308
22. 99mTc]TRODAT-1 SPET for the evaluation of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging 31 (2004) 155-161
23. Hyde T.M., Stacey M.E., Coppola R., Handel S.F., Rickler K.C., and Weinberger D.R. Cerebral morphometric abnormalities in Tourette's syndrome: a quantitative MRI study of monozygotic twins. Neurology 45 (1995) 1176-1182
24. Krause K.H., Dresel S., Krause J., Kung H.F., Tatsch K., and Lochmuller H. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate. Journal of Neurology 249 (2002) 1116-1118
25. Krause J., la Fougere C., Krause K.H., Ackenheil M., and Dresel S.H. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. European Archives of Psychiatry and Clinical Neuroscience 255 (2005) 428-431
26. 99mTc]TRODAT-1. European Journal of Nuclear Medicine 23 (1996) 1527-1530
27. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. European Journal of Nuclear Medicine 24 (1997) 372-380
28. 99mTc]TRODAT-1: a dopamine transporter imaging agent. Journal of Nuclear Medicine 40 (1999) 150-158
29. Leckman J.F., Riddle M.A., Hardin M.T., Ort S.I., Swartz K.L., Stevenson J., and Cohen D.J. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry 28 (1989) 566-573
30. 123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. American Journal of Psychiatry 152 (1995) 1359-1361
31. Meyer P., Bohnen N.I., Minoshima S., Koeppe R.A., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., and Albin R.L. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology 53 (1999) 371-374
32. Mozley P.D., Stubbs J.B., Plössl K., Dresel S.H., Barraclough E.D., Alavi A., Araujo L.I., and Kung H.F. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. Journal of Nuclear Medicine 39 (1998) 2069-2076
33. 99mTc] TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. Journal of Nuclear Medicine 41 (2000) 584-589
34. Muller-Vahl K.R., Berding G., Brucke T., Kolbe H., Meyer G.J., Hundeshagen H., Dengler R., Knapp W.H., and Emrich H.M. Dopamine transporter binding in Gilles de la Tourette syndrome. Journal of Neurology 247 (2000) 514-520
35. 123I]FP-CIT and a dedicated small animal SPECT. European Journal of Nuclear Medicine and Molecular Imaging 32 (2005) 308-313
36. Nomura Y., and Segawa M. Neurology of Tourette's syndrome (TS) as a developmental dopamine disorder: a hypothesis. Brain & Development 25 (2003) 37-42
37. Peterson B.S., Thomas P., Kane M.J., Scahill L., Zhang H., Bronen R., King R.A., Leckman J.F., and Staib L. Basal ganglia volumes in patients with Gilles de la Tourette syndrome. Archives of General Psychiatry 60 (2003) 415-424
38. 123I]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica 109 (2004) 140-146
39. Shapiro E., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J., and Phillips R.A. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 46 (1989) 722-730
40. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 20 (1998) 22-33
41. Singer H.S., Hahn I.H., and Moran T.H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Annals of Neurology 30 (1991) 558-562
42. Singer H.S., Szymanski S., Giuliano J., Yokoi F., Dogan A.S., Brasic J.R., Zhou Y., Grace A.A., and Wong D.F. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. American Journal of Psychiatry 159 (2002) 1329-1336
43. 123I]beta-CIT SPECT study. European Neuropsychopharmacology 11 (2001) 69-74
44. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., and Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 155 (1998) 1325-1331
45. Volkow N.D., Fowler J.S., Wang G.J., Ding Y.S., and Gatley S.J. Mechanism of action of methylphenidate: insights from PET imaging studies. Journal of Attention Disorders 6 (2002) 31-43
46. Wolf S.S., Jones D.W., Knable M.B., Gorey J.G., Lee K.S., Hyde T.M., Coppola R., and Weinberger D.R. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 273 (1996) 1225-1227
47. Wong D.F., Singer H.S., Brandt J., Shaya E., Chen C., Brown J., Kimball A.W., Gjedde A., Dannals R.F., Ravert H.T., Wilson P.D., and Wagner Jr. H.N. D2-like dopamine receptor density in Tourette syndrome measured by PET. Journal of Nuclear Medicine 38 (1997) 1243-1247